Amalgatome MD/SK Tissue Bank Line

About Exsurco Medical

Exsurco Medical, founded in 2016, has developed the proprietary Amalgatome platform, a rotary dermatome technology designed for superior maneuverability and consistent tissue thickness. The company commercializes two product lines: the Amalgatome MD and SK for tissue bank (cadaveric) use, and the Amalgatome SD, an FDA-cleared surgical device for skin grafting and debridement in burn and trauma surgery. Early clinical testimonials and a peer-reviewed consensus paper highlight significant potential benefits in operative speed, graft quality, and donor site yield, positioning Exsurco as a disruptive player in the established dermatome market.

Therapeutic Areas